Clinical trial · Interventional
Analgesic Efficacy of Sacral Neuromodulation for Pelvic Cancer Pain: A Preliminary Report
Does Sacral Neuromodulation Relieve Chronic Pelvic Cancer Pain, Compared With Medical Treatment?
NCT04549818CI-TRIAL-00047181unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
in this trial, we will test the analgesic efficacy of sacral neuromodulation for patients with pelvic cancer, complaining of chronic pelvic pain in comparison to medical treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Pain | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| sacral neuromodulation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- sacral neuromodulation
- description
- Sacral neuromodulation group, will be treated with Stimulation of the sacral nerve roots by placement of a lead and generator, typically using an implanted InterStim® device that provides constant electrical stimulation to the S 2, 3 and 4 nerve roots, for 2-week trial stimulation
- interventionNames
- Device: sacral neuromodulation
- type
- NO_INTERVENTION
- label
- medical therapy
- description
- this group will be treated with sustained release morphine tablets for pain control
Primary outcomes (1)
- measure
- The change of intensity of pain
- timeFrame
- The outcome will be measured at day 15 postoperatively.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Age, 18-70 * Pain localized to the pelvic and perineal region * The pain is due to pelvic cancer or chronic pelvic pain after pelvic surgery for cancer * The intensity of pain assessed by VAS (visual analogue pain scale) \> 7 * Importantly, the included participants should gain \> 50% reduction of their pain in response to sacral roots block, S2,3 and 4 with bupivacaine 0.5%, 2 ml for each root Exclusion Criteria: * Coagulopathy * Infection at site of maneuver * Abnormal Psychological behavior that interfere with integrity of obtained data
References
Publications (0)
Data not yet available
No reference posted for this study.